Current perspectives on the epidemiology of gastrointestinal stromal tumours

European Journal of Cancer, Supplement

Volumn 4, Issue 3, 2006, Pages 4-9

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Gastrointestinal stromal tumour; Imatinib mesylate; KIT; PDGFR; Tyrosine Idnase inhibitors

Indexed keywords

EPITOPE; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CAUCASIAN; CELL PROLIFERATION; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TRACT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; MALIGNANT TRANSFORMATION; MESENCHYME; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; OUTCOME ASSESSMENT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; SARCOMA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33646337945     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(06)80468-4     Document Type: Article

References (56)

1. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 103 4 (2005) 821-829
2. Goettsch W.G., Bos S.D., Breekveldt-Postma N., Casparie M., Herings R.M., and Hogendoorn P.C. Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. Eur J Cancer 41 18 (2005) 2868-2872
3. Tryggvason G., Gislason H.G., Magnusson M.K., and Jonasson J.G. Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117 2 (2005) 289-293
4. Miettinen M., and Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 438 1 (2001) 1-12
5. Tran T., Davila J.A., and El-Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100 1 (2005) 162-168
6. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics, 1996. CA Cancer J Clin 46 1 (1996) 5-27
7. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259 (1994) 1-31
8. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, andmolecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 1 (2005) 52-68
9. Kim K.M., Kang D.W., Moon W.S., et al. Gastrointestinal stromal tumors in Koreans: It's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci 20 6 (2005) 977-984
10. de Silva C.M., and Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9 1 (2003) 13-19
11. Geramizadeh B., Bahador A., Ganjei-Azar P., and Asadi A. Neonatal gastrointestinal stromal tumor. Report of a case and review of literature. J Pediatr Surg 40 3 (2005) 572-574
12. Price R., Daly F., Pennington C.R., and McMurdo M.E. Nutritional supplementation of very old people at hospital discharge increases muscle strength: a randomised controlled trial. Gerontology 51 3 (2005) 179-185
13. Prakash S., Sarran L., Socci N., et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases andreview of the literature. J Pediatr Hematol Oncol 27 4 (2005) 179-187
14. Horton K.M., Juluru K., Montogomery E., and Fishman E.K. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. J Comput Assist Tomogr 28 6 (2004) 811-817
15. Hersh M.R., Choi J., Garrett C., and Clark R. Imaging gastrointestinal stromal tumors. Cancer Control 12 2 (2005) 111-115
16. Eisenberg B.L., and Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11 5 (2004) 465-475
17. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33 5 (2002) 459-465
18. Chen T.W., Liu H.D., Shyu R.V., et al. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571. World J Gastroenterol 11 2 (2005) 260-263
19. Miettinen M., El-Rifai W., and L HLS L.J. Evaluation of malignancy andprognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33 5 (2002) 478-483
20. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodrnff J.M., and Brennan M.E. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 1 (2000) 51-58
21. Joensuu H., Fletcher C., Dimitrijevic S., Silberman S., Roberts P., and Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3 11 (2002) 655-664
22. Ng E.H., Pollock R.E., Munsell M.F., Atkirrson E.N., and Romsdahl M.M. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215 1 (1992) 68-77
23. Conlon K.C., Casper E.S., and Brennan M.F. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 2 1 (1995) 26-31
24. Clary B.M., DeMatteo R.P., Lewis J.J., Leung D., and Brennan M.F. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 8 4 (2001) 290-299
25. Duensing A., Heinrich M.C., Fletcher C.D., and Fletcher J.A. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 22 1 (2004) 106-116
26. Kindblom L.G., Remotti H.E., Aldenborg F., and Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 5 (1998) 1259-1269
27. Levy A.D., Remotti H.E., Thompson W.M., Sobin L.H., and Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 23 2 (2003) 283-304
28. quiz 532. Levy A.D., Remotti H.E., Thompson W.M., Sobin L.H., and Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 23 2 (2003) 456
29. Yamaguchi U., Hasegawa T., Masuda T., et al. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch 445 2 (2004) 142-150
30. Sarlomo-Rikala M., Kovatich A.J., Barusevicius A., and Miettinen M. CD117 a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11 8 (1998) 728-734
31. West R.D., Corless C.L., Chen X., et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165 1 (2004) 107-113
32. Blay P., Astudillo A., Buesa J.M., et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10 12Pt1 (2004) 4089-4095
33. Duensing A., Joseph N.E., Medeiros F., et al. Protein Kinase C theta (PKCdheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64 15 (2004) 5127-5131
34. Motegi A., Sakurai S., Nakayama H., Sano T., Oyama T., and Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT negative tumors. Pathol Int 55 3 (2005) 106-112
35. discussion 547-548. Blair S.L., Al-Refaie W.B., Wang-Rodriguez J., Behling C., Ali M.W., and Moossa A.R. Gastrointestinal stromal tumors express ras oncogene: a potential role for diagnosis and treatment. Arch Surg 140 6 (2005) 543-547
36. Hirota S., Nishida T., Isozaki K., et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193 4 (2001) 505-510
37. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 18 (2004) 3813-3825
38. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 23 (2005) 5337-5364
39. Heinrich M.C., Shoemaker J.S., Corless C.L., et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). 2005 ASCO Annual Meeting (2005) 3s
40. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 5607 (2003) 708-710
41. Nishida T., Hirota S., Taniguchi M., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 19 4 (1998) 323-324
42. Chompret A., Kannengiesser C., Barrois M., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 126 1 (2004) 318-331
43. Candelaria M., de la Garza J., and Duenas-Gonzalez A. A clinical and biological overview of gastrointestinal stromal tumors. Med Oncol 22 1 (2005) 1-10
44. Kinoshita K., Hirota S., Isozaki K., et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202 1 (2004) 80-85
45. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56 1 (1996) 100-104
46. Buchdunger E., Ciof C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 1 (2000) 139-145
47. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 3 (2000) 925-932
48. Okuda K., Weisberg E., Gilliland D.G., and Griffin J.D. ARG tyrosine kinase activity is inhibited by STI571. Blood 97 8 (2001) 2440-2448
49. Dewar A.L., Cambareri A.C., Zannettino A.C., et al. Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib. Blood 105 8 (2005) 3127-3132
50. Tuveson D.A., Willis N.A., Jacks T., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20 36 (2001) 5054-5058
51. DeMatteo R.P. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (ST1571). Ann Surg Oncol 9 9 (2002) 831-839
52. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 14 (2001) 1052-1056
53. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 9291 (2001) 1421-1423
54. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
55. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 Suppl 5 (2002) S83-S87
56. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 14 (2003) 2006-2011